VACCINES MARKET ANALYSIS

Vaccines Market Size and Trends

The Global Vaccines Market is estimated to be valued at USD 77.12 Billion in 2024 and is expected to reach USD 116.10 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 6% from 2024 to 2031.

To learn more about this report, Request sample copy

The global vaccines market is expected to witness a positive trend over the forecast period. Increased immunization programs by various governments and private organizations to curb the prevalence of diseases like influenza, measles, and etc. is driving the market growth. Furthermore, rising investments in research and development of novel vaccines for diseases without available preventions such as HIV/AIDS, and Ebola will provide new opportunities in the coming years. Introduction of technologically advanced vaccines and growing adult immunization are expected to augment the demand for vaccines between 2024 to 2031.

Growing awareness about immunization programs

With the advancements in medical research and technology over the past few decades, immunization has become one of the most effective interventions to protect public health. Several factors have led to higher awareness about vaccination in recent times globally. Health organizations like WHO and UNICEF have been carrying out extensive immunization drives and education campaigns globally, with a focus on developing nations. They have effectively educated the communities about vaccine-preventable diseases and how immunization can help eradicate them. As a result of these initiatives, people now understand better how immunization not only protects individuals but also contributes to herd immunity. The message that vaccinating children is every parent's responsibility has resonated strongly.

With growing digital penetration, access to health information is much wider than before. People extensively research online regarding recommended vaccination schedules and types of vaccines. They stay updated on disease outbreaks through news and social media. This has made them more cognizant of immunization as a key preventive healthcare measure. Also, as literacy levels improve across geographies, so does the health-seeking behaviour of societies. They recognize vaccination as the optimal way to shield against common but life-threatening illnesses. As more families witness the direct benefits of immunization first-hand among friends and relatives, its value becomes apparent. With no or minimal cases of diseases like polio, pertussis, and measles in communities following high immunization rates, vaccination gains trust as an effective public health intervention. Testimonials from those immunized spread the positive message furthers. The overall advancement in societal development has enhanced the perception and trust in modern medicine, including vaccines.

To learn more about this report, Request sample copy

Increasing investments by pharmaceutical companies for vaccine development

Pharmaceutical companies have recognized lucrative opportunities in the vaccines market, considering its steady rise driven by the above factors as well as others. This has motivated them to increase investment in vaccine R&D, as well as expansion activities to capitalize on the market’s potential. Vaccine production requires sophisticated technology and facilities due to the delicate nature of live attenuated and subunit vaccine components. It also necessitates extensive clinical trials to ensure efficacy and safety. Meeting these challenges demands heavy investment, which companies are willing to undertake seeing the vaccines business as a long-term proposition. They have been channelling greater budgets into new vaccine R&D focusing on both pediatric as well as adult diseases. This has already resulted in vaccines for HPV, Hepatitis B, pneumonia, etc. to enter the market.

Besides R&D spending, companies are expanding manufacturing plants and enhancing their production capacities. Many have set up or are setting up new facilities especially in high-growth vaccine markets like Asia and Africa. This is to reduce transportation costs as well as address local regulations. Companies are also making strategic acquisitions that boost their vaccine portfolios and market reach as well. For instance, Merck’s acquisition of Themis and GSK’s acquisition of Novartis Vaccines business. Furthermore, innovative financing and partnership models have come up, with GAVI acting as a major advocacy and funding agency. This has bolstered pharmaceuticals companies’ confidence in their investments, as viable business models and market readiness get demonstrated. Strong economic incentives encourage ongoing contributions to the vaccine portfolio, thereby strengthening public health protection. Thus, increased investments by major pharmaceutical companies have accelerated vaccine supply and development of novel vaccines.